These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4447785)

  • 1. Serum oestradiol-17 beta in women with benign and malignant breast disease.
    England PC; Skinner LG; Cottrell KM; Sellwood RA
    Br J Cancer; 1974 Dec; 30(6):571-6. PubMed ID: 4447785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex hormones in breast disease.
    England PC; Skinner LG; Cottrell KM; Sellwood RA
    Br J Surg; 1975 Oct; 62(10):806-9. PubMed ID: 1191940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings: Serum oestradiol 17 beta in normal premenopausal women and in patients with benign and malignant breast disease.
    Skinner LG; England PC; Cottrell KM; Selwood RA
    Br J Cancer; 1974 Aug; 30(2):176-7. PubMed ID: 4419442
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum prolactin concentrations in benign breast disease throughout the menstrual cycle.
    Cole EN; Sellwood RA; England PC; Griffiths K
    Eur J Cancer (1965); 1977 Jun; 13(6):597-603. PubMed ID: 880967
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum oestradiol in women with and without breast disease.
    Bennett IC; McCaffrey JF; McCaffrey E; Wyatt B
    Br J Cancer; 1990 Jan; 61(1):142-6. PubMed ID: 2393409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum oestradiol-17 beta in normal women.
    England PC; Skinner LG; Cottrell KM; Sellwood RA
    Br J Cancer; 1974 Jun; 29(6):462-9. PubMed ID: 4854260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC; Sellwood RA; Knyba RE; Irvine JD
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract]   [Full Text] [Related]  

  • 8. Benign breast disease I: hormonal investigation.
    Sitruk-Ware R; Sterkers N; Mauvais-Jarvis P
    Obstet Gynecol; 1979 Apr; 53(4):457-60. PubMed ID: 571588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen binding and risk factors for breast cancer.
    Ingram DM; Nottage EM; Willcox DL; Roberts A
    Br J Cancer; 1990 Feb; 61(2):303-7. PubMed ID: 2310682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous assays of cancer associated antigens in benign and malignant breast diseases.
    Franchimont P; Zangerle PF; Hendrick JC; Reuter A; Colin C
    Cancer; 1977 Jun; 39(6 Suppl):2806-12. PubMed ID: 68808
    [No Abstract]   [Full Text] [Related]  

  • 11. [Benign breast diseases: hormonal studies in 125 cases (author's transl)].
    Mauvais-Jarvis P; Kuttenn F; Mowszowicz I; Sitruk-Ware R
    Nouv Presse Med; 1977 Dec; 6(44):4115-8. PubMed ID: 600762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of plasma prolactin to 17-B oestradiol in women with tumours of the breast.
    Jones MK; Ramsay ID; Collins WP; Dyer GI
    Eur J Cancer (1965); 1977 Oct; 13(10):1109-12. PubMed ID: 923610
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum oestradiol-17 beta and prolactin concentrations during the luteal phase in women with benign breast disease.
    Walsh PV; McDicken IW; Bulbrook RD; Moore JW; Taylor WH; George WD
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1345-51. PubMed ID: 6542005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonal function of the ovarian corpus luteum during benign mammary diseases].
    Mauvais-Jarvis P; Tamborini A; Sterkers N; Ohlgiesser G; Mowszowicz I
    J Gynecol Obstet Biol Reprod (Paris); 1975; 4(7):965-70. PubMed ID: 1219052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk.
    Bruning PF; Bonfrèr JM; Hart AA
    Br J Cancer; 1985 Apr; 51(4):479-84. PubMed ID: 4038881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of placental protein five (PP5) and pregnancy-specific glycoprotein (SP1) in benign and malignant breast disease.
    Bremner RD; Nisbet AD; Herriot R; Horne CH; McArdle C; Crawford D; Bohn H
    Oncodev Biol Med; 1981; 2(1-2):55-62. PubMed ID: 6975467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
    Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
    Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients.
    Haagensen DE; Mazoujian G; Holder WD; Kister SJ; Wells SA
    Ann Surg; 1977 Mar; 185(3):279-85. PubMed ID: 843124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer.
    Bulbrook RD; Moore JW; Clark GM; Wang DY; Tong D; Hayward JL
    Eur J Cancer (1965); 1978 Dec; 14(12):1369-75. PubMed ID: 738341
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum prolactin and oestradiol levels in women with cyclical mastalgia.
    Watt-Boolsen S; Andersen AN; Blichert-Toft M
    Horm Metab Res; 1981 Dec; 13(12):700-2. PubMed ID: 7319468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.